论文部分内容阅读
目的观察黄连素联合莫沙必利治疗糖尿病性便秘的临床疗效。方法将96例糖尿病性便秘患者随机分为对照组和治疗组,每组48例。对照组采用莫沙必利治疗,治疗组在对照组的基础上加用黄连素,疗程均为2周。检测两组患者治疗前后空腹血糖(FBG)、餐后2h血糖(2h PBS)和果糖胺(FA)。计算便秘症状评分,观察临床疗效。结果两组患者治疗前后FBG、2h PBS和FA均下降,且治疗组均低于对照组(P<0.05);治疗后两组患者便秘症状评分(排便困难、Bristol评分、排便时间、排便次数及腹胀)均下降,且治疗组均低于对照组(P<0.05)。治疗后两组患者临床症状均改善,且治疗组总有效率高于对照组(P<0.05)。结论黄连素联合莫沙必利治疗糖尿病性便秘可取得更好的临床疗效。
Objective To observe the clinical efficacy of berberine and mosapride in the treatment of diabetic constipation. Methods 96 patients with diabetic constipation were randomly divided into control group and treatment group, 48 cases in each group. The control group was treated with mosapride, and the treatment group was given berberine on the basis of the control group. The course of treatment was 2 weeks. Fasting blood glucose (FBG), 2h postprandial blood glucose (2h PBS) and fructosamine (FA) were measured before and after treatment in both groups. Calculate the symptom score of constipation, observe the clinical curative effect. Results Both FBG and FA of two groups decreased before and after treatment, and both groups were lower than the control group (P <0.05). After treatment, the scores of constipation (dyspareunia, Bristol score, defecation time, defecation frequency, Bloating) decreased, and the treatment group were lower than the control group (P <0.05). After treatment, the clinical symptoms of both groups were improved, and the total effective rate of the treatment group was higher than that of the control group (P <0.05). Conclusion Berberine combined with mosapride treatment of diabetic constipation can achieve better clinical efficacy.